Table 3.

VIP trial results by absence or presence of classic neovascular lesions

Outcome at 2 years (primary outcome of loss of at least 15 letters of VA)	VIP PDT group	VIP Placebo	VIP RR (95% CI)	TAP PDT group	TAP Placebo	TAP RR (95% CI)
Whole trial*	121/225	76/114	0.81 (0.68 to 0.96)	189/402	129/207	0.75 (0.65 to 0.88)
No classic*	91/166	63/92	0.80 (0.66 to 0.97)	18/41	14/20	0.63 (0.40 to 0.98)
>0% classic†	30/59‡	13/22‡	0.86 (0.56 to 1.32)	106/202§	58/104§	0.94 (0.76 to 1.17) §

*As reported in published paper.

†Mostly >0% and <50% according to table of participants.

‡Not reported; calculated by subtraction.

§Minimally classic TAP trial results.